Latest Health News

Infratil Limited has achieved a significant milestone with S&P Global Ratings assigning it a BBB+ investment grade credit rating, signaling strong financial health and promising future expansion opportunities.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.

CONNEQT Health has raised $3.1 million through an institutional placement to fuel growth of its Pulse vascular health device, supported by both new and existing investors including its largest shareholder.

Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.

Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.

Stockland has announced an estimated ordinary dividend of AUD 0.09 per security for the six months ending December 2025, payable in February 2026, alongside a Dividend Reinvestment Plan offering a 1% discount.

Assetora Limited has obtained a Supreme Court injunction restraining external receivers, allowing its directors to maintain control while agreeing on payments to noteholders.

DGL Group Limited has secured an extension of its syndicated debt facility to March 2027 and received a waiver protecting it from default amid its ASX suspension. The company anticipates its securities will be reinstated on the ASX by early 2026 following a half-year audit.

Scout Security outlines a bold transformation with the acquisition of Roo Inc., expansion into insuretech, and a pivot to AI-driven smart security solutions, positioning itself for accelerated growth and profitability.

4DMedical secures Cleveland Clinic as the third major US academic medical centre to adopt its CT – VQ™ respiratory imaging technology, marking rapid commercial traction post-FDA clearance.

Bapcor Limited has obtained unanimous lender approval to temporarily ease its Net Leverage Ratio covenant, supporting its ongoing turnaround efforts through mid-2026.

nib holdings limited signals higher-than-expected non-recurring expenses in the first half of 2026, impacting statutory profit but leaving underlying performance steady.